Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCLA.

Learn more about UC TechAlerts - Save your searches and get notified of new UC technologies

Redox Responsive Polymeric Nanocapsules for Protein Delivery

Researchers at UCLA have developed novel nanocapsules that preferentially direct protein delivery to the intracellular space of cells. The invention overcomes the major challenge of stability for protein-based therapeutics.

Modification of Peptides Using bis(thioether) ArylBridge (tABTM) Approach

Researchers in UCLA’s Department of Medicine have developed a novel peptide bridging technology that is a more efficient and cost-effective alternative to stapling technology for the manufacturing of peptide therapeutics. 

Inhibitors Of The N-Terminal Domain Of The Androgen Receptor

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

Application of Topical Resveratrol in the Treatment of Acne

Researchers in UCLA Department of Dermatology have demonstrated through in vitro experiments that resveratrol, an ingredient in antioxidants and anti-aging products, generates sustained bactericidal and anti-inflammatory effects against P. acnes, the bacteria involved in the pathogenesis of acne.

Diagnostic Biomarkers for the Early Detection of Woman's Cancer, Including Ovarian, Uterine and Colon

Researchers at UCLA's Jonsson Comprehensive Cancer Center have identified a naturally occurring human protein, apolipoprotein (ApoA-I), which helps kill ovarian cancer cells and improves overall survival. Experimental data suggest that apoA-I and apoA-I mimetic peptides are promising therapeutic agents for the treatment of human ovarian cancer. The powerful anti-cancer effect of apoA-I is demonstrated with strong inhibition of tumor growth and spreading in animal models of ovarian cancer.

Azuvirins: Novel Peptides with Antiviral and Antineoplastic Potential

UCLA researchers have designed and produced a series of small peptides that demonstrate outstanding synergistic efficacy with radiation in treating tumor growth and development. In addition, the peptides are potent inhibitors of viral infection from HIV and herpes simplex virus (HSV).

Second-Generation Estrogen Receptor Down-Regulators for Medical Therapy

UCLA researchers in the School of Medicine have developed a series of novel estrogen receptor antagonists for breast cancer therapy.

Anti-Cspg4 Fusions with Type I Interferon for the Treatment of Malignancy

UCLA researchers have developed antibody-interferon fusion proteins that show high efficacy against cancer cells in vitro and in vivo.

Novel Antiviral Compounds to Treat Enterovirus Infections

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

New Compounds For The Treatment Of Diseases Related To Protein Misfolding

UCLA researchers in the Department of Neurology with an international team of scientists have developed compounds for therapeutic use in protein misfolding diseases.

Small Molecules to Facilitate Therapeutic Exon Skipping

Investigators at UCLA have discovered a series of small molecules to facilitate therapeutic exon skipping. The use of these identified molecules may enhance the effectiveness of antisense oligonucleotide agents currently in clinical development.

Vectors for Antibody Expression

Brief description not available

Netrin-1 Compounds as Post-MI and Post-Angioplasty Therapeutics as well as for Treating Renal and CNS Reperfusion Injury

UCLA researchers have invented a method of decreasing myocardial injury and infarct size through the intravenous administration of the netrin-1 or netrin-1-derived peptides during a cardiac event. These agents have powerful cardioprotective effects and provide a novel and effective therapy for the treatment of myocardial infarction.

Small Molecule Inhibitors of Cardiovascular and Renal Ectopic Calcification

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

Antibody Therapy for Inhibiting Bladder Cancer and Prostate Cancer Metastasis

UCLA has a robust intellectual property position on antibody-based diagnostics and therapeutics against N-cadherin for the treatment and detection of prostate and bladder cancers. The research and development leading to this promising technology has been conducted by Dr. Robert Reiter, Professor of Urology and Director of UCLA’s Prostate Cancer Program.

Novel Anti-TfR Antibodies For Improved Cancer Treatment

Dr. Manuel Penichet and colleagues at the UCLA Departments of Surgery and Microbiology, Immunology, and Molecular Genetics have developed a novel anti-human transferrin receptor (TfR) antibody for the treatment of incurable hematological malignancies such as multiple myeloma and aggressive lymphoma.

Peripherally-Acting Cannabinoid Receptor Agonists for Chronic Pain

Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability.  The compounds represent promising therapeutics for treating chronic pain.   

Inhibition of Aminoacylase 3 (Aa3) in the Treatment of Cancer

UCLA researchers have developed aminoacylase 3 (AA3) inhibitors to treat hepatocellular carcinoma (HCC) and other Ras driven cancers. 

  • Go to Page: